Researchers Examine Etiology of Ibrutinib Discontinuation in CLL

This article originally appeared here.
Share this content:
Researchers Examine Etiology of Ibrutinib Discontinuation in CLL
Researchers Examine Etiology of Ibrutinib Discontinuation in CLL

(HealthDay News) -- For patients with chronic lymphocytic leukemia (CLL), the Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective, and prognosis is poor after discontinuation, according to a study published online Feb. 26 in JAMA Oncology. The research identifies, for the first time, baseline factors associated with ibrutinib therapy discontinuation.

Kami J. Maddocks, M.D., from The Ohio State University in Columbus, and colleagues examined features associated with discontinuation of ibrutinib therapy and outcomes in a cohort of 308 patients participating in four clinical trials of ibrutinib. Patients were followed for a median of 20 months.

During follow-up, the researchers found that 232 patients remained on therapy, 31 discontinued due to disease progression (including Richter's transformation [RT] or progressive CLL), and 45 discontinued for other reasons. RT seemed to occur early (cumulative incidence at 12 months, 4.5 percent), while CLL progression appeared later (cumulative incidence at 12 months, 0.3 percent). Following RT and CLL progression, the median survival was 3.5 and 17.6 months, respectively. Sequencing on peripheral blood revealed mutations in BTK from two of eight patients with RT; deep sequencing revealed BTK or PLCG2 mutations in all 11 patients with CLL progression.

"These data show that continued clinical trials are needed in this disease and that scientific progress cannot stop even with a breakthrough drug like ibrutinib," the authors write. "Patients with RT remain a high research priority to identify new targets and new therapies."

Several authors disclosed financial ties to pharmaceutical companies, including Pharmacyclics, which was involved in funding some of the trials.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Vit D Independently, Inversely Tied to Cholesterol in Children

Vit D Independently, Inversely Tied to Cholesterol in ...

Gene variants do not modify the associations of 25(OH)D with lipids

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Lower degree of susceptibility to ibalizumab for nine of 10 patients with virology failure, rebound

Weight Gain After Quitting Smoking May Up T2DM Risk

Weight Gain After Quitting Smoking May Up T2DM ...

But temporary increase in type 2 diabetes risk does not attenuate benefits on total, CVD mortality

is free, fast, and customized just for you!




Already a member?

Sign In Now »